| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 16, 2019FDA Cleared and CE Marked, Telescope Enters Global Market with Design Innovations to Enable Smooth Delivery of Coronary Stents and Balloons
DUBLIN - May 16, 2019 - Medtronic plc (NYSE:MDT), a global leader in percutaneous coronary intervention (PCI) innovation, today announced its entrance into the guide extension catheter market with...
-
Feb 26, 2019FDA Approval Allows Interventional Cardiologists Access to Resolute DES Technology to Treat De Novo CTO
DUBLIN - February 26, 2019 - Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its Resolute Drug-Eluting Stent (DES) platform (including the Resolute...
-
Nov 8, 2018FDA-Approved Study Furthers Medtronic Commitment to Generate Meaningful Clinical Evidence for Use of Renal Denervation to Treat Uncontrolled Hypertension
DUBLIN - November 8, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin a clinical trial to evaluate the Symplicity Spyral(TM) renal...
-
Sep 21, 2018TCT18: BIONYX Study Shows Strong Performance with Durable Polymer Resolute Onyx DES in Head-to-Head Comparison with Biodegradable Polymer DES
DUBLIN and SAN DIEGO - September 22, 2018 - Investigators today unveiled new clinical data from the physician-initiated BIONYX study, representing the first all-comers analysis in nearly 2,500...
-
May 24, 2018Onyx 1-Month OCT Study Provides Potential Insights on DAPT Duration in Complex Patients Following Stent Implantation
DUBLIN and PARIS- May 24, 2018 - Investigators today unveiled clinical data from the independently run Onyx 1-Month OCT Study, which showed strong early vessel healing in a patient population that...
-
May 23, 2018Late-Breaking SPYRAL HTN-ON MED Study at EuroPCR Indicates RDN Lowers Blood Pressure in Hypertensive Patients in Presence of BP Medication
DUBLIN and PARIS - May 23, 2018 - Medtronic plc (NYSE:MDT) today announced first-ever-data from the SPYRAL HTN-ON MED Study. Initial study results found statistically significant and clinically...
-
May 16, 2018Medtronic Received IDE Approval from FDA to Generate Clinical Evidence with Resolute Onyx DES to Support Future Application for Expanded Indication in U.S.
DUBLIN - May 16, 2018 - Medtronic plc (NYSE: MDT) today announced the initiation of a clinical study in the U.S. to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of...
-
Apr 9, 2018Pivotal Trial Now Underway to Study Effect of Investigational Procedure in Patients with High Blood Pressure
DUBLIN - April 9, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the...
-
Feb 26, 2018FDA Approved, Resolute Onyx 2.0 mm DES Technology Tackles Clinical Challenge of Treating Coronary Artery Disease in Previously Untreatable Patients
DUBLIN - February 26, 2018 - Designed specifically for small vessels, Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute...
-
Aug 28, 2017Published Simultaneously in The Lancet, the Late-Breaking SPYRAL HTN-OFF MED Study at ESC Successfully Isolates RDN Treatment Effect to Show Compelling Efficacy and Safety of Hypertension Procedure
DUBLIN and BARCELONA - August 28, 2017 - Medtronic plc (NYSE:MDT) today announced its intent to move forward with a new renal denervation pivotal trial following positive first results from a...
-
May 18, 2017First-Ever Study on 2.0 mm DES, EuroPCR Late-Breaking Data Show Exceptional Deliverability and No Stent Thrombosis for the Resolute Onyx DES
DUBLIN and PARIS- May 18, 2017 - Medtronic plc (NYSE: MDT) today announced that the Resolute Onyx(TM) Drug-Eluting Stent (DES) met its primary endpoint of Target Lesion Failure (TLF) at one year...
-
May 1, 2017Engineered for Exceptional Deliverability, Advanced DES Technology Features Thinner Struts, Enhanced Visibility and the Broadest Size Matrix in the U.S.
DUBLIN – May 1, 2017 – Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx™ Drug-Eluting Stent (DES). The...
-
Feb 13, 2017Full Line of Innovative Transradial Products and Comprehensive Training Programs Reinforce Medtronic's Commitment to Optimizing the Treatment of Heart Disease
DUBLIN - Feb. 13, 2017 - Medtronic plc (NYSE: MDT) today announced that its market-leading coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line and several...
-
Oct 31, 2016Featured 'First Report' RevElution Trial at TCT Highlights the Potential Benefits of First-of-its-Kind Polymer-Free Technology with Controlled and Sustained Drug Delivery for Rapid Vessel Healing
DUBLIN and WASHINGTON, D.C. - Oct. 31, 2016 - Medtronic plc (NYSE: MDT) unveiled today the first clinical outcomes of its novel Drug-Filled Stent (DFS) from the RevElution Trial at the...
-
Apr 3, 2016Medtronic Announces Early Data and Completes Enrollment in CE Mark Cohort in Drug-Filled Stent TrialRevElution Trial with Next-Gen Polymer-Free Stent Continues to Show Excellent Rapid Healing and Controlled Drug Delivery at ACC.16
DUBLIN and CHICAGO - April 3, 2016 - Medtronic plc (NYSE: MDT) announced new clinical data today from one of the endpoints in the RevElution Trial for its novel, next-generation Drug-Filled Stent...
-
Feb 1, 2016New Extra-Large Vessel Stent Sizes and Indications in the EU Expand Treatment Options for Patients with Coronary Artery Disease
DUBLIN - February 1, 2016 - Medtronic plc (NYSE: MDT) today announced the recent CE (Conformité Européene) Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES, a next...
-
Nov 30, 2014First and Only DES with Novel CoreWire Technology Allows for Thinner, Stronger Struts, Enhanced Deliverability and Radiopacity without Compromising Structural Strength
MINNEAPOLIS - Nov. 3, 2014 - Optimizing the treatment of coronary artery disease with a new foundation for future stent innovations, Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Europé
-
Nov 5, 2014Fourth-quarter net sales up 7%; Medical Devices sales up 8%
DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 5, 2014-- Covidien plc (NYSE: COV) today announced financial results for the fourth quarter of fiscal 2014. Fourth-quarter net sales of $2.73 billion...
-
Sep 11, 2014Superior Deliverabilityi and Uncompromising Performance Distinguishes New Angioplasty Balloon
MINNEAPOLIS -- Sept. 11, 2014 -- Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of the NC Euphora(TM) Noncompliant Balloon...
-
Jul 25, 2014Net sales up 4%; Medical Devices sales up 5%
DUBLIN, Ireland--(BUSINESS WIRE)--Jul. 25, 2014-- Covidien plc (NYSE: COV) today announced financial results for the third quarter of fiscal 2014. Third-quarter net sales of $2.69 billion...
-
May 20, 2014Q4 Revenue of $4.6 Billion Grew 3% at Constant Currency; 2% as Reported
MINNEAPOLIS - May 20, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2014, which ended April 25, 2014. The company reported worldwide...
-
May 20, 2014Noncompliant Balloon Provides Superior Deliverability and Controlled Growth for Challenging Coronary Angioplasty Procedures
MINNEAPOLIS -- May 20, 2014 -- Continuing its commitment to bringing advanced and clinically relevant interventional technologies to market, Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité
-
Apr 25, 2014Net sales up 3% (up 4%, excluding foreign exchange rate movement)
DUBLIN, Ireland--(BUSINESS WIRE)--Apr. 25, 2014-- Covidien plc (NYSE: COV) today announced financial results for the second quarter of fiscal 2014. Second-quarter net sales of $2.60 billion...
-
Apr 7, 2014
ISTANBUL - April 7, 2014 - Medtronic, Inc. today announced that one of its subsidiaries has acquired a majority of the shares of Biostar, which will assume the distribution of Medtronic products...
-
Mar 30, 2014Six-Month Analysis of First 1,000 Patients Enrolled in Real-World Patient Registry Presented at ACC.14
MINNEAPOLIS and WASHINGTON, D.C. - March 30, 2014 - Medtronic, Inc. (NYSE: MDT), announced today further analysis of six-month follow-up data from the first 1,000 patients enrolled in the Global...